Dave Weldon will not be the next director of the CDC, after the White House pulled his nomination just hours ahead of a ...

Montara Therapeutics has raised $20 million in an expanded seed financing to advance a pipeline of preclinical CNS candidates ...

Endpoints Health Tech newsletter wins SABEW award for business journalism, recognized for coverage of healthcare industry ...

GoodRx’s brand new CEO, Wendy Barnes, says her job is not so much to fix anything, but to speed up the company’s current ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

Endo to merge with Mallinckrodt in $6.7B deal. Combined revenue expected at $3.6B by 2025. Deal to close in H2 2025.

Mallinckrodt Pharmaceuticals and Endo are in talks over a potential merger worth about $7 billion, according to a report from ...

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster ...

Ascletis' ASC47 shows 1.7% weight loss vs. placebo in Phase 1b trial, Vivace gets a $35M Series D for VT3989, and Harbour BioMed launches obesity startup Élancé Therapeutics.

Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.

Ono Pharmaceuticals is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare ...

Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching ...